JPWO2021023657A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2021023657A5 JPWO2021023657A5 JP2022506618A JP2022506618A JPWO2021023657A5 JP WO2021023657 A5 JPWO2021023657 A5 JP WO2021023657A5 JP 2022506618 A JP2022506618 A JP 2022506618A JP 2022506618 A JP2022506618 A JP 2022506618A JP WO2021023657 A5 JPWO2021023657 A5 JP WO2021023657A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- antigen binding
- amino acid
- binding protein
- acid sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 125000003275 alpha amino acid group Chemical group 0.000 claims 25
- 102000025171 antigen binding proteins Human genes 0.000 claims 23
- 108091000831 antigen binding proteins Proteins 0.000 claims 23
- 108020004707 nucleic acids Proteins 0.000 claims 23
- 102000039446 nucleic acids Human genes 0.000 claims 23
- 150000007523 nucleic acids Chemical class 0.000 claims 23
- 210000004027 cell Anatomy 0.000 claims 12
- 239000000427 antigen Substances 0.000 claims 9
- 102000036639 antigens Human genes 0.000 claims 9
- 108091007433 antigens Proteins 0.000 claims 9
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims 8
- 239000013598 vector Substances 0.000 claims 7
- 239000008194 pharmaceutical composition Substances 0.000 claims 6
- 150000001413 amino acids Chemical class 0.000 claims 4
- 108090000765 processed proteins & peptides Proteins 0.000 claims 4
- 108091008874 T cell receptors Proteins 0.000 claims 3
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 claims 3
- 230000000890 antigenic effect Effects 0.000 claims 3
- 201000010099 disease Diseases 0.000 claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- 230000002068 genetic effect Effects 0.000 claims 3
- 230000002062 proliferating effect Effects 0.000 claims 3
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 210000001744 T-lymphocyte Anatomy 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- 239000012634 fragment Substances 0.000 claims 2
- 238000006467 substitution reaction Methods 0.000 claims 2
- 108091026890 Coding region Proteins 0.000 claims 1
- 241000699802 Cricetulus griseus Species 0.000 claims 1
- 102100028972 HLA class I histocompatibility antigen, A alpha chain Human genes 0.000 claims 1
- 108010075704 HLA-A Antigens Proteins 0.000 claims 1
- 239000012736 aqueous medium Substances 0.000 claims 1
- 102000023732 binding proteins Human genes 0.000 claims 1
- 108091008324 binding proteins Proteins 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 239000000032 diagnostic agent Substances 0.000 claims 1
- 229940039227 diagnostic agent Drugs 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- -1 host cell Substances 0.000 claims 1
- 238000002955 isolation Methods 0.000 claims 1
- 210000002901 mesenchymal stem cell Anatomy 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 210000001672 ovary Anatomy 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 108010005636 polypeptide C Proteins 0.000 claims 1
- 102000004196 processed proteins & peptides Human genes 0.000 claims 1
- 238000000746 purification Methods 0.000 claims 1
- 238000003259 recombinant expression Methods 0.000 claims 1
- 239000003381 stabilizer Substances 0.000 claims 1
- 210000000130 stem cell Anatomy 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025127372A JP2025163112A (ja) | 2019-08-02 | 2025-07-30 | 修飾二特異性抗ｃｄ３抗体 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962882364P | 2019-08-02 | 2019-08-02 | |
| DE102019121022.4A DE102019121022A1 (de) | 2019-08-02 | 2019-08-02 | Rekrutierungsagens, das zusätzlich ein MHC-Molekül bindet |
| US62/882,364 | 2019-08-02 | ||
| DE102019121022.4 | 2019-08-02 | ||
| PCT/EP2020/071655 WO2021023657A1 (en) | 2019-08-02 | 2020-07-31 | Modified bi specific anti cd3 antibodies |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025127372A Division JP2025163112A (ja) | 2019-08-02 | 2025-07-30 | 修飾二特異性抗ｃｄ３抗体 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022543387A JP2022543387A (ja) | 2022-10-12 |
| JP2022543387A5 JP2022543387A5 (https=) | 2023-08-08 |
| JPWO2021023657A5 true JPWO2021023657A5 (https=) | 2023-08-08 |
Family
ID=72050824
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022506618A Pending JP2022543387A (ja) | 2019-08-02 | 2020-07-31 | 修飾二特異性抗ｃｄ３抗体 |
| JP2025127372A Pending JP2025163112A (ja) | 2019-08-02 | 2025-07-30 | 修飾二特異性抗ｃｄ３抗体 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025127372A Pending JP2025163112A (ja) | 2019-08-02 | 2025-07-30 | 修飾二特異性抗ｃｄ３抗体 |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US20210032370A1 (https=) |
| EP (1) | EP4007778A1 (https=) |
| JP (2) | JP2022543387A (https=) |
| KR (1) | KR20220041196A (https=) |
| CN (1) | CN114206932B (https=) |
| AU (1) | AU2020325562A1 (https=) |
| BR (1) | BR112022001902A2 (https=) |
| CA (1) | CA3148936A1 (https=) |
| IL (1) | IL290267A (https=) |
| TW (1) | TW202112824A (https=) |
| WO (1) | WO2021023657A1 (https=) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUE058957T2 (hu) | 2016-12-08 | 2022-10-28 | Immatics Biotechnologies Gmbh | Új T-sejt receptorok és velük végzett immunterápia |
| WO2018139634A1 (ja) * | 2017-01-30 | 2018-08-02 | 学校法人日本医科大学 | アデノ随伴ウイルス（ａａｖ）キャプシドタンパク質の変異体 |
| SG11202000025SA (en) * | 2017-07-14 | 2020-02-27 | Immatics Biotechnologies Gmbh | Improved dual specificity polypeptide molecule |
| DE102019121007A1 (de) | 2019-08-02 | 2021-02-04 | Immatics Biotechnologies Gmbh | Antigenbindende Proteine, die spezifisch an MAGE-A binden |
| US11912771B2 (en) | 2021-03-09 | 2024-02-27 | Cdr-Life Ag | MAGE-A4 peptide-MHC antigen binding proteins |
| EP4304725A1 (en) | 2021-03-09 | 2024-01-17 | CDR-Life AG | Rabbit-derived antigen binding protein nucleic acid libraries |
| US12162940B2 (en) * | 2021-05-05 | 2024-12-10 | Immatics Biotechnologies Gmbh | BMA031 antigen binding polypeptides |
| US20250231186A1 (en) * | 2022-04-20 | 2025-07-17 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Coupling assay for t cell specificity (cats) and method of its use |
| CN114957487B (zh) * | 2022-05-24 | 2024-01-26 | 北京先声祥瑞生物制品股份有限公司 | 一种重组结核分枝杆菌融合蛋白及其在结核诊断中应用 |
| WO2023246911A1 (zh) * | 2022-06-24 | 2023-12-28 | 北京可瑞生物科技有限公司 | 基于t细胞受体的双特异性多肽分子及其用途 |
| KR20250067130A (ko) | 2022-09-14 | 2025-05-14 | 씨디알-라이프 아게 | Mage-a4 펩티드 이중 t 세포 연결체 |
| AU2024289515A1 (en) | 2023-07-05 | 2026-01-08 | Enara Bio Limited | Bispecific polypeptide molecule |
| AU2024293296A1 (en) * | 2023-07-20 | 2026-02-26 | University Of Utah Research Foundation | Multi-specific self-assembled drug-free macromolecular t-cell engagers |
| TW202506719A (zh) | 2023-07-27 | 2025-02-16 | 德商艾瑪提克生物技術有限公司 | 針對mageb2之抗原結合蛋白 |
| WO2025233420A1 (en) | 2024-05-07 | 2025-11-13 | Immatics Biotechnologies Gmbh | Use of anti-cancer molecules |
| WO2025233431A1 (en) | 2024-05-07 | 2025-11-13 | Immatics Biotechnologies Gmbh | Heteromeric proteins comprising three heteromerization improving substitution, production, combinations and applications thereof |
| GB2641580A (en) | 2024-06-07 | 2025-12-10 | T Therapeutics Ltd | Tumour-transforming multispecific proteins |
| WO2026025031A1 (en) | 2024-07-26 | 2026-01-29 | Modernatx, Inc. | Mrna encoding mageb2 tcer molecule |
| WO2026078231A1 (en) | 2024-10-11 | 2026-04-16 | T-Therapeutics Limited | Soluble non-aggregating immune ligand |
Family Cites Families (64)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
| JPS6023084B2 (ja) | 1979-07-11 | 1985-06-05 | 味の素株式会社 | 代用血液 |
| WO1981001145A1 (en) | 1979-10-18 | 1981-04-30 | Univ Illinois | Hydrolytic enzyme-activatible pro-drugs |
| US4640835A (en) | 1981-10-30 | 1987-02-03 | Nippon Chemiphar Company, Ltd. | Plasminogen activator derivatives |
| US4496689A (en) | 1983-12-27 | 1985-01-29 | Miles Laboratories, Inc. | Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer |
| DE3675588D1 (de) | 1985-06-19 | 1990-12-20 | Ajinomoto Kk | Haemoglobin, das an ein poly(alkenylenoxid) gebunden ist. |
| AU597574B2 (en) | 1986-03-07 | 1990-06-07 | Massachusetts Institute Of Technology | Method for enhancing glycoprotein stability |
| US4861719A (en) | 1986-04-25 | 1989-08-29 | Fred Hutchinson Cancer Research Center | DNA constructs for retrovirus packaging cell lines |
| US4791192A (en) | 1986-06-26 | 1988-12-13 | Takeda Chemical Industries, Ltd. | Chemically modified protein with polyethyleneglycol |
| GB8705477D0 (en) | 1987-03-09 | 1987-04-15 | Carlton Med Prod | Drug delivery systems |
| US4975278A (en) | 1988-02-26 | 1990-12-04 | Bristol-Myers Company | Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells |
| US5202238A (en) | 1987-10-27 | 1993-04-13 | Oncogen | Production of chimeric antibodies by homologous recombination |
| US5204244A (en) | 1987-10-27 | 1993-04-20 | Oncogen | Production of chimeric antibodies by homologous recombination |
| US5278056A (en) | 1988-02-05 | 1994-01-11 | The Trustees Of Columbia University In The City Of New York | Retroviral packaging cell lines and process of using same |
| US5208020A (en) | 1989-10-25 | 1993-05-04 | Immunogen Inc. | Cytotoxic agents comprising maytansinoids and their therapeutic use |
| US5670488A (en) | 1992-12-03 | 1997-09-23 | Genzyme Corporation | Adenovirus vector for gene therapy |
| MD1367C2 (ro) | 1992-11-13 | 2000-11-30 | Idec Pharmaceuticals Corporation | Metode de tratament al limfomului celulelor B, anticorpi anti-CD20, hibridom. |
| DE69434860T2 (de) | 1993-02-22 | 2007-03-15 | The Rockefeller University | Herstellung von helfer-freien retroviren mit hohem titer mittels transienter transfektion |
| FR2712812B1 (fr) | 1993-11-23 | 1996-02-09 | Centre Nat Rech Scient | Composition pour la production de produits thérapeutiques in vivo. |
| IL116816A (en) | 1995-01-20 | 2003-05-29 | Rhone Poulenc Rorer Sa | Cell for the production of a defective recombinant adenovirus or an adeno-associated virus and the various uses thereof |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| CN1241944C (zh) | 1995-09-11 | 2006-02-15 | 协和发酵工业株式会社 | 抗人白介素－5受体α链的抗体 |
| US6013516A (en) | 1995-10-06 | 2000-01-11 | The Salk Institute For Biological Studies | Vector and method of use for nucleic acid delivery to non-dividing cells |
| GB9809951D0 (en) | 1998-05-08 | 1998-07-08 | Univ Cambridge Tech | Binding molecules |
| JP4972264B2 (ja) | 1999-12-06 | 2012-07-11 | ボード オブ トラスティーズ オブ ザ ユニバーシティ オブ イリノイ | 高親和性ｔｃｒタンパク質および方法 |
| DE10225139A1 (de) | 2002-05-29 | 2004-02-26 | Immatics Biotechnologies Gmbh | Verfahren zur Identifizierung von immunreaktiven Peptiden |
| DE60327795D1 (de) | 2002-11-09 | 2009-07-09 | Immunocore Ltd | T zell rezeptor "display" |
| GB0308731D0 (en) | 2003-04-15 | 2003-05-21 | Anticancer Therapeutic Inv Sa | Method of radiotherapy |
| JP2007519910A (ja) | 2004-01-28 | 2007-07-19 | イマティクス バイオテクノロジーズ ゲーエムベーハー | 腫瘍関連ペプチドの同定および定量方法 |
| CN111909273B (zh) | 2007-08-29 | 2024-03-26 | 塞诺菲-安万特股份有限公司 | 人源化的抗-cxcr5抗体、其衍生物及它们的应用 |
| US9840695B2 (en) | 2009-04-28 | 2017-12-12 | Agriculture Victoria Services Pty Ltd | Plant technology |
| GB201006360D0 (en) | 2010-04-16 | 2010-06-02 | Immatics Biotechnologies Gmbh | Method for differentially quantifying naturally processed HLA-restricted peptides for cancer, autoimmune and infectious diseases immunotherapy development |
| TWI588156B (zh) | 2011-03-28 | 2017-06-21 | 賽諾菲公司 | 具有交叉結合區定向之雙重可變區類抗體結合蛋白 |
| AU2014236769B2 (en) | 2013-03-15 | 2018-09-27 | Amgen Inc. | Heterodimeric bispecific antibodies |
| GB201423361D0 (en) | 2014-12-30 | 2015-02-11 | Immatics Biotechnologies Gmbh | Method for the absolute Quantification of naturally processed HLA-Restricted cancer peptides |
| CR20170383A (es) | 2015-01-23 | 2017-11-22 | Sanofi Sa | Anticuerpos anti-cd3, anticuerpos anti-cd-123 y anticuerpos biespecíficos que se unen específicamente a cd3 y/o cd123 |
| GB201504502D0 (en) | 2015-03-17 | 2015-04-29 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against pancreatic cancer and other cancers |
| GB201505305D0 (en) | 2015-03-27 | 2015-05-13 | Immatics Biotechnologies Gmbh | Novel Peptides and combination of peptides for use in immunotherapy against various tumors |
| GB201505585D0 (en) | 2015-03-31 | 2015-05-13 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides and scaffolds for use in immunotherapy against renal cell carinoma (RCC) and other cancers |
| GB201507719D0 (en) | 2015-05-06 | 2015-06-17 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides and scaffolds thereof for use in immunotherapy against colorectal carcinoma (CRC) and other cancers |
| GB201510771D0 (en) | 2015-06-19 | 2015-08-05 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy and methods for generating scaffolds for the use against pancreatic cancer |
| GB201511191D0 (en) | 2015-06-25 | 2015-08-12 | Immatics Biotechnologies Gmbh | T-cell epitopes for the immunotherapy of myeloma |
| GB201511546D0 (en) | 2015-07-01 | 2015-08-12 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers |
| GB201511792D0 (en) | 2015-07-06 | 2015-08-19 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against esopageal cancer and other cancers |
| GB201512369D0 (en) | 2015-07-15 | 2015-08-19 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against epithelial ovarian cancer and other cancers |
| GB201513921D0 (en) | 2015-08-05 | 2015-09-23 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against prostate cancer and other cancers |
| US10130693B2 (en) | 2015-08-28 | 2018-11-20 | Immatics Biotechnologies Gmbh | Peptides, combination of peptides and scaffolds for use in immunotherapeutic treatment of various cancers |
| GB201517538D0 (en) | 2015-10-05 | 2015-11-18 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against small cell lung cancer and other cancers |
| WO2017060201A1 (en) | 2015-10-09 | 2017-04-13 | Immatics Biotechnologies Gmbh | Anti-wt1/hla-specific antibodies |
| GB201521746D0 (en) | 2015-12-10 | 2016-01-27 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against CLL and other cancers |
| GB201521894D0 (en) | 2015-12-11 | 2016-01-27 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against various cancers |
| GB201522667D0 (en) | 2015-12-22 | 2016-02-03 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against breast cancer and other cancers |
| GB201602918D0 (en) | 2016-02-19 | 2016-04-06 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against NHL and other cancers |
| GB201603568D0 (en) | 2016-03-01 | 2016-04-13 | Immatics Biotechnologies Gmbh | Efficient treatment options including peptides and combination of peptide and cell based medicaments for use in immunotherapy against urinary bladder cancer |
| GB201603987D0 (en) | 2016-03-08 | 2016-04-20 | Immatics Biotechnologies Gmbh | Uterine cancer treatments |
| GB201604492D0 (en) | 2016-03-16 | 2016-04-27 | Immatics Biotechnologies Gmbh | Transfected t-cells and t-cell receptors for use in immunotherapy against cancers |
| GB201604494D0 (en) | 2016-03-16 | 2016-04-27 | Immatics Biotechnologies Gmbh | Transfected T-Cells and T-Cell receptors for use in immunotherapy against cancers |
| DE102016115246C5 (de) | 2016-08-17 | 2018-12-20 | Immatics Biotechnologies Gmbh | Neue t-zellrezeptoren und deren verwendung in immuntherapie |
| DE102016123847B3 (de) | 2016-12-08 | 2018-04-05 | Immatics Biotechnologies Gmbh | Neue T-Zellrezeptoren und deren Verwendung in Immuntherapie |
| DE102016123859B3 (de) | 2016-12-08 | 2018-03-01 | Immatics Biotechnologies Gmbh | Neue T-Zellrezeptoren und deren Verwendung in Immuntherapie |
| DE102017106305A1 (de) | 2017-03-23 | 2018-09-27 | Immatics Biotechnologies Gmbh | Neue T-Zellrezeptoren und deren Verwendung in Immuntherapien gegen prame-positive Krebsarten |
| DE102017114737A1 (de) | 2017-06-30 | 2019-01-03 | Immatics Biotechnologies Gmbh | Neue T-Zellrezeptoren und deren Verwendung in Immuntherapie |
| SG11202000025SA (en) * | 2017-07-14 | 2020-02-27 | Immatics Biotechnologies Gmbh | Improved dual specificity polypeptide molecule |
| DE102018100967B4 (de) | 2018-01-17 | 2019-08-14 | Immatics US, Inc. | Verfahren zur feststellung der wirksamkeit von viralen vektoren |
-
2020
- 2020-07-30 US US16/943,313 patent/US20210032370A1/en not_active Abandoned
- 2020-07-31 WO PCT/EP2020/071655 patent/WO2021023657A1/en not_active Ceased
- 2020-07-31 CA CA3148936A patent/CA3148936A1/en active Pending
- 2020-07-31 CN CN202080056129.8A patent/CN114206932B/zh active Active
- 2020-07-31 EP EP20754675.5A patent/EP4007778A1/en active Pending
- 2020-07-31 AU AU2020325562A patent/AU2020325562A1/en not_active Abandoned
- 2020-07-31 JP JP2022506618A patent/JP2022543387A/ja active Pending
- 2020-07-31 KR KR1020227007087A patent/KR20220041196A/ko active Pending
- 2020-07-31 BR BR112022001902A patent/BR112022001902A2/pt unknown
- 2020-07-31 TW TW109125975A patent/TW202112824A/zh unknown
-
2022
- 2022-01-31 IL IL290267A patent/IL290267A/en unknown
- 2022-11-02 US US18/052,009 patent/US20230203200A1/en active Pending
-
2025
- 2025-07-30 JP JP2025127372A patent/JP2025163112A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPWO2021023657A5 (https=) | ||
| TWI531377B (zh) | 骨關節炎及疼痛之治療 | |
| US20180208648A1 (en) | Gdf11 binding proteins and uses thereof | |
| WO2019169314A1 (en) | IgM Fc AND J-CHAIN MUTATIONS THAT AFFECT IgM SERUM HALF-LIFE | |
| US20250243273A1 (en) | Humanized anti-basigin antibodies and the use thereof | |
| JP2020504087A (ja) | ４−１ｂｂ結合タンパク質及びその使用 | |
| EP4317186A1 (en) | Nanobody targeting bcma and application thereof | |
| CN108136012A (zh) | 靶向分子的抗原结合构建体 | |
| JP2012516153A (ja) | Ｉｌ−１結合タンパク質 | |
| KR20150038556A (ko) | ＴＮＦ-α 결합 단백질 | |
| TW201124534A (en) | Dual variable domain immunoglobulins and uses thereof | |
| WO2022143552A1 (zh) | Pd-1结合分子及其应用 | |
| CA3149350A1 (en) | Igm glycovariants | |
| TW201741339A (zh) | 投與結合至cd33及cd3之雙特異性建構體來用於治療骨髓樣白血病之方 法中 | |
| WO2023143535A1 (zh) | 一种靶向il-18bp的抗体及其应用 | |
| CN113862300A (zh) | 具有共同轻链的转基因兔 | |
| WO2021093753A1 (zh) | 一种能够与人4-1bb结合的分子及其应用 | |
| JPWO2023186120A5 (https=) | ||
| JPWO2021070181A5 (https=) | ||
| WO2024234988A1 (zh) | 特异性结合cd38的抗体及其制法和应用 | |
| NZ614207B2 (en) | Treatment of osteoarthritis and pain | |
| HK1168110A (en) | Il-1 binding proteins |